Treace Medical Concepts, Inc.: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Aug 7, 2025 and accepted by EDGAR at Aug 7, 2025, 16:17 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-04-01 to 2025-06-30 | $47.4m | us-gaap:Revenues |
| Revenue | 6 months2025-01-01 to 2025-06-30 | $100.0m | us-gaap:Revenues |
| Cost of revenue | 3 months2025-04-01 to 2025-06-30 | $9.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2025-01-01 to 2025-06-30 | $20.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-04-01 to 2025-06-30 | $37.8m | us-gaap:GrossProfit |
| Gross profit | 6 months2025-01-01 to 2025-06-30 | $79.6m | us-gaap:GrossProfit |
| Research and development | 3 months2025-04-01 to 2025-06-30 | $5.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-01-01 to 2025-06-30 | $11.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$17.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-01-01 to 2025-06-30 | −$32.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-04-01 to 2025-06-30 | $1.3m | us-gaap:InterestExpense |
| Interest expense | 6 months2025-01-01 to 2025-06-30 | $2.6m | us-gaap:InterestExpense |
| Net income | 3 months2025-04-01 to 2025-06-30 | −$17.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | −$33.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-01-01 to 2025-06-30 | −$0.53 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-01-01 to 2025-06-30 | −$0.53 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 63,006,891 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-30 | 62,843,337 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | $1.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2025-01-01 to 2025-06-30 | $8.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-06-30 | $8.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $147.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $206.4m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $41.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $108.8m | us-gaap:Liabilities |
| Long-term debt | At period end2025-06-30 | $53.5m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | At period end2025-06-30 | $1.1m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2025-06-30 | $97.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-25-105059. Last ingested by Listed: Oct 29, 2026, 04:31 ET. Listed shows no prices and gives no investment advice.